Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Septerna, Inc. stock logo
SEPN
Septerna
$12.32
+0.1%
$10.39
$4.17
$28.99
$548.31MN/A657,735 shs34,961 shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$5.90
-7.5%
$4.26
$2.41
$10.37
$456.49M2.341.23 million shs471,528 shs
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$4.35
+5.8%
$5.58
$2.02
$10.37
$232.52M0.33376,915 shs198,473 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$13.25
$15.30
$5.80
$22.15
$50.58M-0.06953 shs4 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Septerna, Inc. stock logo
SEPN
Septerna
-1.91%+2.50%+17.57%+106.20%+1,230,999,900.00%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-0.31%+16.45%+32.99%+85.71%-22.51%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-3.75%-8.46%-26.08%-33.50%+89.40%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%-1.85%-6.82%+10.42%+60.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Septerna, Inc. stock logo
SEPN
Septerna
1.1413 of 5 stars
3.40.00.00.00.00.00.6
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.464 of 5 stars
4.61.00.00.03.91.70.6
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
1.4817 of 5 stars
3.51.00.00.00.01.70.6
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Septerna, Inc. stock logo
SEPN
Septerna
2.80
Moderate Buy$26.75117.13% Upside
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.17
Buy$15.10156.15% Upside
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
3.00
Buy$10.00129.89% Upside
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ZIVO, SLDB, TKNO, and SEPN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2025
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$8.00
7/21/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$16.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/23/2025
Septerna, Inc. stock logo
SEPN
Septerna
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$26.00
6/17/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
5/22/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$16.00
5/19/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/16/2025
Septerna, Inc. stock logo
SEPN
Septerna
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$20.00 ➝ $25.00
5/16/2025
Septerna, Inc. stock logo
SEPN
Septerna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $18.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Septerna, Inc. stock logo
SEPN
Septerna
$1.08M508.31N/AN/A$9.46 per share1.30
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/A$3.43 per shareN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$37.74M6.16N/AN/A$1.55 per share2.81
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K3,190.87N/AN/A($0.81) per share-16.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Septerna, Inc. stock logo
SEPN
Septerna
-$71.80MN/A0.00N/AN/AN/AN/AN/A8/21/2025 (Estimated)
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$26.75M-$0.48N/AN/AN/A-60.90%-28.48%-19.73%8/12/2025 (Estimated)
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$4.93N/AN/AN/AN/A-2,240.92%8/12/2025 (Estimated)

Latest ZIVO, SLDB, TKNO, and SEPN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.51N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Septerna, Inc. stock logo
SEPN
Septerna
-$0.38-$0.49-$0.11-$0.49N/A$0.22 million
5/15/2025Q1 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.53-$0.59-$0.06-$0.59N/AN/A
5/8/2025Q1 2025
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$0.11-$0.09+$0.02-$0.09$9.41 million$9.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Septerna, Inc. stock logo
SEPN
Septerna
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Septerna, Inc. stock logo
SEPN
Septerna
N/A
32.19
32.19
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
10.89
10.89
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.17
5.64
4.71
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17

Institutional Ownership

CompanyInstitutional Ownership
Septerna, Inc. stock logo
SEPN
Septerna
N/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
13.81%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
12.83%

Insider Ownership

CompanyInsider Ownership
Septerna, Inc. stock logo
SEPN
Septerna
4.30%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
1.90%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
12.50%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
48.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Septerna, Inc. stock logo
SEPN
Septerna
N/A44.56 million42.64 millionN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.52 million66.95 millionOptionable
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
24053.44 million46.76 millionNot Optionable
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
103.82 million2.91 millionNot Optionable

Recent News About These Companies

Harmony Biosciences Holdings
Regencell Bioscience Holdings Ltd RGC
ZIVO Bioscience Announces Uplisting to OTCQB Market
Ideaya Biosciences
Dare Bioscience Inc DARE
Zivo Bioscience Inc (ZIVO) USD0.001
Zivo Bioscience Inc ZIVO
Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Septerna stock logo

Septerna NASDAQ:SEPN

$12.32 +0.01 (+0.08%)
As of 10:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$5.90 -0.48 (-7.46%)
As of 10:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Alpha Teknova stock logo

Alpha Teknova NASDAQ:TKNO

$4.35 +0.24 (+5.84%)
As of 10:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$13.25 0.00 (0.00%)
As of 07/18/2025

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.